Ivabradina Ampdr (Ivabradine Hydrochloride)

• Ivabradina Ampdr acts on the cardiac If current to manage conditions characterized by excessive heart rate.
• Chronic stable angina pectoris: reduces the frequency of angina attacks and improves exercise tolerance.
• Heart failure with reduced ejection fraction: lowers heart rate, improving symptoms and decreasing hospitalisation risk.
• Coronary artery disease with sinus tachycardia: helps control heart rate, enhancing overall cardiac efficiency.

• Ivabradine Hydrochloride selectively inhibits the funny (If) current in the sinoatrial node. By blocking this pacemaker current, it slows depolarisation of the node, producing a dose‑dependent reduction in heart rate without impairing myocardial contractility or ventricular repolarisation.

Ivabradina Ampdr may cause a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects

• Visual disturbances (phosphenes) especially at treatment initiation.
• Bradycardia (heart rate below 50 bpm).
• Headache.
• Dizziness or light‑headedness.
• Fatigue.
• Blurred vision.

Serious or Rare Side Effects

• Symptomatic severe bradycardia requiring medical intervention.
• Atrial fibrillation or other supraventricular arrhythmias.
• Marked hypotension leading to syncope.
• Persistent visual impairment or retinal disturbances.

Before prescribing Ivabradina Ampdr, clinicians should consider several safety aspects.

• Cardiac monitoring: patients with severe conduction disease or sick‑sinus syndrome require careful observation.
• Dose adjustment: reduce dose in moderate hepatic impairment.
• Avoid in: patients with acute decompensated heart failure or unstable angina.
• Caution with concomitant bradycardic agents such as beta‑blockers or calcium‑channel blockers.
• Pregnancy: safety category unknown; use only if potential benefit justifies risk.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ivabradina Ampdr can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine exposure.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.
• Concomitant bradycardic agents (e.g., high‑dose beta‑blockers): risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely)

• Digoxin: monitor plasma levels for potential additive effects on heart rate.
• Verapamil or diltiazem: observe for enhanced bradycardia.
• Antihypertensives: watch for additive hypotensive responses.